Tsuchimoto Kim R
SEC Form 4 insider trading activity
Tsuchimoto Kim R has filed 2 SEC Form 4 filings (14 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 29, 2026.
On the most recent filing, Tsuchimoto Kim R is listed as Director at Monopar Therapeutics. Inside the rolling window, Tsuchimoto Kim R reported no open-market purchases and 1 open-market sale totaling $456K in MNPR.
Companies traded
Other insiders at MNPR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$456K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Tsuchimoto Kim R made?
Tsuchimoto Kim R has filed 2 SEC Form 4 filings (14 transaction rows) across 1 company since 2026.
Which companies does Tsuchimoto Kim R trade?
Tsuchimoto Kim R has filed SEC Form 4 disclosures for 1 company, including MNPR.
When was Tsuchimoto Kim R's most recent SEC Form 4 filing?
Tsuchimoto Kim R's most recent SEC Form 4 filing on Tracefour is dated Aug 29, 2026.
What is Tsuchimoto Kim R's total buy and sell value in the current window?
Inside the rolling retention window, Tsuchimoto Kim R bought $0 and sold $456K based on SEC Form 4 filings.
What was Tsuchimoto Kim R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,090 MNPR shares on 2026-08-26, worth $456K, per SEC Form 4 filings.